BIOMAT Database Logo BIOMAT Database Logo

Phage in the time of cholera. 2006

Joshua S Weitz, and Hyman Hartman

UI MeSH Term Description Entries
D002771 Cholera An acute diarrheal disease endemic in India and Southeast Asia whose causative agent is VIBRIO CHOLERAE. This condition can lead to severe dehydration in a matter of hours unless quickly treated. Vibrio cholerae Infection,Choleras,Infection, Vibrio cholerae,Infections, Vibrio cholerae,Vibrio cholerae Infections
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001435 Bacteriophages Viruses whose hosts are bacterial cells. Phages,Bacteriophage,Phage
D012621 Seasons Divisions of the year according to some regularly recurrent phenomena usually astronomical or climatic. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 6th ed) Seasonal Variation,Season,Seasonal Variations,Variation, Seasonal,Variations, Seasonal
D014734 Vibrio cholerae The etiologic agent of CHOLERA. Bacillus cholerae,Bacillus cholerae-asiaticae,Liquidivibrio cholerae,Microspira comma,Pacinia cholerae-asiaticae,Spirillum cholerae,Spirillum cholerae-asiaticae,Vibrio albensis,Vibrio cholera,Vibrio cholerae-asiaticae,Vibrio comma
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D018570 Risk Assessment The qualitative or quantitative estimation of the likelihood of adverse effects that may result from exposure to specified health hazards or from the absence of beneficial influences. (Last, Dictionary of Epidemiology, 1988) Assessment, Risk,Benefit-Risk Assessment,Risk Analysis,Risk-Benefit Assessment,Health Risk Assessment,Risks and Benefits,Analysis, Risk,Assessment, Benefit-Risk,Assessment, Health Risk,Assessment, Risk-Benefit,Benefit Risk Assessment,Benefit-Risk Assessments,Benefits and Risks,Health Risk Assessments,Risk Analyses,Risk Assessment, Health,Risk Assessments,Risk Benefit Assessment,Risk-Benefit Assessments

Related Publications

Joshua S Weitz, and Hyman Hartman
[Polyvalent diagnostic cholera phage].
June 1976, Zhurnal mikrobiologii, epidemiologii i immunobiologii,
Joshua S Weitz, and Hyman Hartman
Characteristics of a cholera phage.
December 1978, Archives of microbiology,
Joshua S Weitz, and Hyman Hartman
Reviving Phage Therapy for the Treatment of Cholera.
February 2019, The Journal of infectious diseases,
Joshua S Weitz, and Hyman Hartman
Properties of the cholera phage PL 163/10.
May 1975, Acta virologica,
Joshua S Weitz, and Hyman Hartman
The time of cholera.
January 2011, The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale,
Joshua S Weitz, and Hyman Hartman
Spectrophotometric characteristics of cholera phage phi2 DNA.
August 1980, The Journal of general virology,
Joshua S Weitz, and Hyman Hartman
Characteristics of a group IV cholera phage.
November 1971, The Journal of general virology,
Joshua S Weitz, and Hyman Hartman
Effects of furazolidone on the reproduction of cholera phage.
March 1973, Indian journal of experimental biology,
Joshua S Weitz, and Hyman Hartman
Ultraviolet inactivation and photoreactivation of the cholera phage 'kappa'.
January 1987, Radiation and environmental biophysics,
Joshua S Weitz, and Hyman Hartman
Characterization of the phage-specific transfer RNA molecules coded by cholera phage phi 149.
October 1988, Virology,
Copied contents to your clipboard!